SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2016 - 2015 - 2014 - 2013

June 2016 Scleroderma News

Cape Breton scleroderma sufferers look to provincial society for support. There appeared to be interest in establishing a Cape Breton chapter of the Scleroderma Society of Nova Scotia in Sydney to help make sufferers aware of the services the society can offer. Cape Breton Post, 05/28/2016. (Also see Causes of Scleroderma: Cluster Studies)

Frequency of circulating topoisomerase–I–specific CD4 T cells predicts presence and progression of interstitial lung disease (ILD) in scleroderma. Topo–I–specific T cells can be reliably quantified in the peripheral blood of patients with scleroderma, exhibit a pro–inflammatory Th17 phenotype, and predict progression of ILD. BioMed Central, Arthritis Research & Therapy, 05/04/2016. (Also see Causes of Scleroderma: B Cells and T Cells and Pulmonary Fibrosis)

Clinical characteristics of scleroderma overlap syndromes (SOV): comparisons with pure scleroderma. SOV rather than pure scleroderma presented in younger Thai scleroderma patients and scleroderma–polymyositis overlap was the most common subtype and its clinical features were similar to those of pure scleroderma. PubMed, Int J Rheum Dis, 04/29/2016. (Also see Scleroderma in Overlap)

Case Report: Type B insulin resistance syndrome with Scleroderma successfully treated with multiple immune suppressants after eradication of Helicobacter pylori infection. The present case suggests H pylori infection–related pathological mechanism may contribute to type B insulin resistance syndrome and autoimmune disorders. BioMed Central, BMC Endocrine Disorders. (Also see Immunosuppressants)

M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. M10 peptide interacts with Smad2 and demonstrates strong antifibrotic effects in vitro and in vivo in an animal model of lung fibrosis and should be considered as a potential therapeutic agent for systemic sclerosis and other fibrosing diseases. PubMed, Transl Res, 2016 Apr;170:99-111. (Also see Skin Fibrosis and Pulmonary Fibrosis)

The Dilemma of Breast Cancer Treatment and Existing Collagen Vascular Disease: A Case of Scleroderma and Review of the Literature. Early stage breast cancer in a patient with severe scleroderma is treated with breast–conserving surgery without radiation. PubMed, Breast J, 04/28/2016. (Also see Cancer and Scleroderma)

Self–assessment of skin tightness severity by scleroderma patients. The respective modified Rodnan skin score assessment by patient versus the physician was highly correlated with a high level of agreement. PubMed, Int J Rheum Dis, 04/29/2016. (Also see Skin Fibrosis)

Pseudo–infarction pattern in diffuse systemic sclerosis (dSSc). Evaluation using cardiovascular magnetic resonance (CMR). CMR unveiled that the pattern of myocardial fibrosis in dSSc with Q waves is due to the systemic disease and not to coronary artery disease. PubMed, Int J Cardiol, 2016 Apr 8;214:465-468. (Also see Diagnosis of Systemic Scleroderma Heart Involvement)

Whole Exome Sequencing (WES) for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis. This study demonstrates the value of WES for the identification of novel gene variants and pathways that may contribute to scleroderma risk and/or severity. PubMed, Arthritis Rheumatol, 04/25/2016. (Also see Causes of Scleroderma: Genetics)

Netrin–1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin–Induced Pulmonary Fibrosis. Netrin–1 regulates bleomycin–induced pulmonary fibrosis in mice and it might be a novel therapeutic target in scleroderma–related interstitial lung disease. PubMed, Arthritis Rheumatol, 2016 May;68(5):1251-61. (Also see Pulmonary Fibrosis)

Esophageal surgeries in systemic sclerosis (SSc) — a systematic review of the literature. There is clearly a need for careful, controlled studies in uniform groups of SSc patients before being able to rationally recommend esophageal surgery for dysphagia/heartburn in SSc. Journal of Scleroderma and Related Disorders, 02/08/2016. (Also see Reflux (Heartburn) Prevention and Treatments)

Go to Scleroderma Medical News: May 2016
 
Recent Donors
See ISN News for recent donors, including memorials for
Patricia Ann Black, Gayle Hedlin, and Janet Paulmenn.
 

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

 
The most important thing in the world to know about scleroderma is sclero.org!
Donate Now
Copyright 1998-2016, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.